The Dutch Parelsnoer Institute - Neurodegenerative diseases; methods, design and baseline results

Pauline Aalten*, Inez H. G. B. Ramakers, Geert Jan Biessels, Peter Paul de Deyn, Huiberdina L. Koek, Marcel G. M. OldeRikkert, Ania M. Oleksik, Edo Richard, Lieke L. Smits, John C. van Swieten, Laura K. Teune, Aad van der Lugt, Frederik Barkhof, Charlotte E. Teunissen, Nico Rozendaal, Frans R. J. Verhey, Wiesje M. van der Flier

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

29 Citations (Web of Science)


Background: The Parelsnoer Institute is a collaboration between 8 Dutch University Medical Centers in which clinical data and biomaterials from patients suffering from chronic diseases (so called "Pearls") are collected according to harmonized protocols. The Pearl Neurodegenerative Diseases focuses on the role of biomarkers in the early diagnosis, differential diagnosis and in monitoring the course of neurodegenerative diseases, in particular Alzheimer's disease. The objective of this paper is to describe the design and methods of the Pearl Neurodegenerative Diseases, as well as baseline descriptive variables, including their biomarker profile. Methods: The Pearl Neurodegenerative Diseases is a 3-year follow-up study of patients referred to a memory clinic with cognitive complaints. At baseline, all patients are subjected to a standardized examination, including clinical data and biobank materials, e.g. blood samples, MRI and cerebrospinal fluid. At present, in total more than 1000 patients have been included, of which cerebrospinal fluid and DNA samples are available of 211 and 661 patients, respectively. First descriptives of a subsample of the data (n = 665) shows that patients are diagnosed with dementia (45%), mild cognitive impairment (31%), and subjective memory complaints (24%). Discussion: The Pearl Neurodegenerative Diseases is an ongoing large network collecting clinical data and biomaterials of more than 1000 patients with cognitive impairments. The project has started with data analyses of the baseline characteristics and biomarkers, which will be the starting point of future specific research questions that can be answered by this unique dataset.
Original languageEnglish
Article number254
JournalBMC Neurology
Publication statusPublished - 31 Dec 2014


  • Dementia
  • Alzheimer's disease
  • Design
  • Biobank
  • Research infrastructure

Cite this